  |
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines.The Company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems.Latest News18 June 2009Oxford BioMedica to Present at Piper Jaffray Europe Conference 4 June 2009Oxford BioMedica Annual General Meeting 1 June 2009Oxford BioMedica Presents Updated TroVax® Phase I/II and II Results at ASCO Annual Meeting InvestorsOxford BioMedica was established in 1995 as a spin out from Oxford University. The company listed on AIM in 1996 and moved to the official list of the London Stock Exchange in 2001. DownloadAnnual Results 2008Share PriceProductsOxford BioMedica has created a broad pipeline of development candidates that use genes as the direct or indirect mediators of a therapeutic effect. The Company’s development pipeline includes treatments for cancer, Parkinson’s disease, age-related macular degeneration, Stargardt disease and motor neuron disease. Cancer Vaccine TrialTRIST is a Phase III clinical trial of Oxford BioMedica’s therapeutic cancer vaccine, TroVax®, in kidney (renal) cancer, which is taking place across approximately 120 centres in USA, Western and Eastern Europe. |
Website by College Hill - Life Sciences |
